This bill aims to enhance public health and welfare in Nebraska by mandating coverage for biomarker testing by health insurers and the medical assistance program starting January 1, 2026. It defines key terms such as "biomarker," "biomarker testing," "consensus statements," and "nationally recognized clinical practice guidelines," which are essential for understanding the scope and application of the testing. The bill stipulates that biomarker testing must be supported by medical and scientific evidence, including FDA-approved tests and clinical guidelines, and it emphasizes the importance of minimizing disruptions in patient care.

Additionally, the bill outlines the procedures for prior authorization requests related to biomarker testing, requiring timely notifications for approvals or denials. It ensures that patients and healthcare providers have access to a straightforward process for requesting exceptions to coverage policies. The legislation aims to improve patient outcomes by facilitating access to necessary diagnostic and treatment tools while ensuring that the coverage aligns with established medical standards.